Charles River Laboratories International, Inc.
CRL
$175.92
$6.653.93%
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.05B | 4.06B | 4.08B | 4.11B | 4.13B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.05B | 4.06B | 4.08B | 4.11B | 4.13B |
| Cost of Revenue | 2.65B | 2.62B | 2.63B | 2.63B | 2.62B |
| Gross Profit | 1.40B | 1.44B | 1.45B | 1.48B | 1.51B |
| SG&A Expenses | 723.62M | 723.51M | 710.48M | 743.26M | 739.95M |
| Depreciation & Amortization | 138.47M | 131.27M | 133.10M | 135.10M | 137.44M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.51B | 3.47B | 3.47B | 3.51B | 3.49B |
| Operating Income | 539.96M | 587.74M | 607.25M | 606.29M | 635.29M |
| Income Before Tax | 93.11M | 518.61M | 540.24M | 549.25M | 581.28M |
| Income Tax Expenses | 67.82M | 90.62M | 94.53M | 98.36M | 100.91M |
| Earnings from Continuing Operations | 25.29 | 427.99 | 445.72 | 450.90 | 480.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.09M | -4.21M | -4.20M | -6.45M | -5.75M |
| Net Income | 22.20M | 423.78M | 441.51M | 444.45M | 474.62M |
| EBIT | 539.96M | 587.74M | 607.25M | 606.29M | 635.29M |
| EBITDA | 892.30M | 927.89M | 938.08M | 928.70M | 949.42M |
| EPS Basic | 0.17 | 8.04 | 8.40 | 8.55 | 9.26 |
| Normalized Basic EPS | 4.94 | 5.80 | 5.89 | 5.79 | 6.05 |
| EPS Diluted | 0.15 | 7.99 | 8.35 | 8.50 | 9.21 |
| Normalized Diluted EPS | 4.91 | 5.77 | 5.85 | 5.76 | 6.01 |
| Average Basic Shares Outstanding | 205.52M | 205.69M | 205.58M | 205.25M | 204.91M |
| Average Diluted Shares Outstanding | 206.34M | 206.83M | 206.85M | 206.47M | 206.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
